| |
 |
Multidisciplinary
approach to the management of all aspects of therapy for haematologic
malignancies. Members of the multi-disciplinary team include
infectious disease physicians, dietitian, pastoral care, palliative
care, psychiatry, physiotherapy, occupational therapy, and social
work |
| |
|
Access
toall radiotherapymodalities including localised and wide field
radiotherapy, total body irradiation and total skin electron
therapy for cutaneous lymphoma |
| |
|
Good
Manufacturing Practice (GMP) grade peripheral blood stem cell
collection, manipulation and storage |
| |
|
Specialized
Late Effects Clinic for long-term follow-up of patients treated
for haematologic malignancies |
| |
|
Integrated
patient care and clinical translational research, such as: |
| |
|
 |
monoclonal
antibody treatment |
|
|
|
|
cellular
therapies |
|
|
|
|
radio
immunotherapy |
|
|
|
|
Antisense
therapy |
| |
|
Clinical
research in all aspects of haematology with a focus on new therapies
including novel chemotherapy agents, radiotherapy administration,
immune therapy and cellular therapies |
| |
|
Participation
in national and international clinical trials of novel therapies
and combinations of therapies |
| |
|
Advanced
Nurse Practitioner in haematology and Nurse Coordinator to facilitate
all aspects of care coordination |
| |
|
On
site high-dependency unit, PET scanner, MRI |
| |
|
High
profile transfusion and apheresis service with close links to
Australian Red Cross Blood Service |
| |
|
Myelodysplastic
Syndrome Foundation designated "Centre of Excellence" |
| |
|
Supportive
care programme focusing on acute supportive care, psychosocial
adjustment, survivorship issues and long term followup |
| |
